
The chief of the Sleep Disorders Clinical Research Program at Massachusetts General Hospital provided perspective on the current major research priorities for the treatment of restless legs syndrome. [WATCH TIME: 3 minutes]

The chief of the Sleep Disorders Clinical Research Program at Massachusetts General Hospital provided perspective on the current major research priorities for the treatment of restless legs syndrome. [WATCH TIME: 3 minutes]

The director of movement disorders at the Banner Sun Health Research Institute talked about how research in essential tremor is revolutionizing the diagnosis and understanding of the movement disorder. [WATCH TIME: 5 minutes]

Amy Perrin Ross, APN, Patricia Melville, NP-C, and Aliza Ben-Zacharia, PhD, DNP, ANP-BC discuss importance of evaluating immunogenicity of biosimilars.

Amy Perrin Ross, APN, Patricia Melville, NP-C, Aliza Ben-Zacharia, PhD, DNP, ANP-BC, and John Kramer, PA-C discuss approval process of biosimilars.

The director of the Movement Disorders Center at Baylor University Medical Center in Dallas, a part of Baylor Scott & White Health, talked about the evolution of treatment for Parkinson disease and the new promising therapies patients may seen over the coming years. [WATCH TIME: 3 minutes]

The professor of neurology at UMass Chan School of Medicine discussed the various impacts Daylight Savings Time has on sleep quality and overall health in children and adolescents. [WATCH TIME: 3 minutes]

Neurology News Network for the week ending July 1, 2023. [WATCH TIME: 3 minutes]

Nicholas Silvestri, MD, FAAN, reviews the standard of care and initial treatments patients with myasthenia gravis (MG) receive, as well as several new treatment options that have recently become available for MG (eculizumab, efgartigimod alfa-fcab, ravulizumab-cwvz).

Nicholas Silvestri, MD, FAAN, discusses the level of awareness of myasthenia gravis (MG) and generalized MG among primary care physicians and the public, and the type of harm patients might sustain if they do not receive timely treatment.

The chief scientific officer at Liberate Bio discussed how through the advancement of nonviral delivery technologies and nucleic acid therapeutics, genetic medicines can potentially bring relief to patients with Duchenne muscular dystrophy. [WATCH TIME: 5 minutes]

The head of the MS Center at Methodist Hospitals and assistant professor of neurology at Indiana University talked about the significance of diversity and the health disparities faced by patients with multiple sclerosis in the LGBTQ+ community. [WATCH TIME: 3 minutes]

The professor of neurology at the University of California, Irvine, talked about social determinants of health in Alzheimer disease and the importance of having diverse populations in clinical trials. [WATCH TIME: 4 minutes]

The pain management specialist and headache neurologist at the University of California San Diego Center for Pain Medicine discussed the different forms of cannabis and the need to conduct larger, multicenter studies to better understand its effects in migraine. [WATCH TIME: 3 minutes]

The undergraduate program director at the University of South Carolina provided perspective on the factors that go into building an equitable and effective medical course for young medical professionals. [WATCH TIME: 5 minutes]

The associate professor at Johns Hopkins School of Nursing provided insight on a presentation at SLEEP 2023, and whether neurofilament light should be more considered when assessing elderly patients with sleep disorders. [WATCH TIME: 5 minutes]

The associate professor of environmental and occupational Health at the University of California, Irvine, talked about the impact of concentrated particulate matter or air pollution on cognitive function in animal models. [WATCH TIME: 5 minutes]

Clinical experts discuss differences and similarities between biosimilars and reference products.

Four advanced practice providers discuss biosimilars and how they can play an important role in healthcare.

At ATMRD 2023, Lori DePorter, global ambassador for the PMD alliance, talked from the patient experience about the need for improved communication between care teams and support groups in Parkinson disease. [WATCH TIME: 3 minutes]

Episode 35 of the AUPN Leadership Minute features Tracey A. Milligan, MD, of New York Medical College; and Carl Gold, MD, MS, of Stanford University. [WATCH TIME: 5 minutes]

The sleep epidemiologist and assistant professor at the Rollins School of Public Health at Emory University discussed the multi-level effort needed to improve sleep issues seen in individuals most impacted by social determinants of health. [WATCH TIME: 3 minutes]

The assistant professor of neurology at Harvard Medical School talked about the prevalence of tension-type headache and how recent advances shed light on its pathophysiological mechanisms, leading to potential new treatments for the condition. [WATCH TIME: 5 minutes]

Neurology News Network for the week ending June 24, 2023. [WATCH TIME: 3 minutes]

The research project manager of the headache program at the Children's Hospital of Philadelphia discussed data that suggest that an unhealthy and imbalanced microbiome may exacerbate the frequency, severity, and duration of migraines. [WATCH TIME: 4 minutes]

Dr Krieger, Dr Brandstadter, and Dr Lublin discuss the advances made in recognizing and managing multiple sclerosis over the last few decades and the challenges that remain.

The chief of the Sleep Disorders Clinical Research Program at Massachusetts General Hospital discussed the benefits opioids have for patients with restless legs syndrome, as well as how they can be safely used as part of treatment strategies. [WATCH TIME: 4 minutes]

The headache specialist at Hartford Healthcare Headache Center talked about her debate at AHS 2023 on why migraine is not a risk factor for dementia. [WATCH TIME: 5 minutes]

The associate professor of neurology at Mayo Clinic discussed the developing field of migraine management during pregnancy and the importance of raising awareness of treatment options during the gestation period. [WATCH TIME: 4 minutes]

Expert geriatric psychiatrists explore a frequently encountered symptom in Alzheimer’s disease, agitation. We will discuss its impact on patient’s and care giver’s quality of life, the current standard of care and the first FDA approved agent for treatment of agitation symptoms in Alzheimer’s disease.

The director of the Pediatric Headache Program at the Children’s Hospital of Philadelphia talked about the usage of an integrated EHR questionnaire to improve the likelihood of specific diagnosis in pediatric headache. [WATCH TIME: 5 minutes]